Grant: CIHR Fellowship
Direct Payment
$150,000.00
Characterization of IGFBP7-mediated apoptosis in oncogenic BRAF melanomas
EF 2009-10
Résumé
Melanoma is a type of cancer that occurs in melanocytes, the pigmented cells of the skin, and is the deadliest form of skin cancer. The incidence of this disease is rising faster than any other cancer (American Cancer Society, 2006) and therapeutic interventions remain only marginally effective. With this in mind, a huge investment is being made to understand melanoma signaling networks in an attempt to identify new targets or combinations of targets for therapeutic intervention.
At the genetic level, greater than 90% of all melanomas show continuous hyperactivity in a particular signaling pathway known as the MAPK pathway, which is responsible for the rapid growth and division of these melanoma cells. In 60% of all melanomas this phenomenon is the result of a particular mutation in the protein BRAF, which is part of the MAPK pathway. Unfortunately drugs that target this pathway do not kill melanoma cells but only slow their growth, which will slow tumour growth but not shrink tumours. Hence these drugs have performed poorly in clinical trials.
The lab of Michael Green at the University of Massachusetts Medical School has discovered that the protein IGFBP7 effective kills melanoma cells that contain this BRAF mutation, shrinking melanoma tumours. The aim of the research proposed here is to fully understand how IGFBP7 kills these cells. This knowledge may further the potential for IGFBP7 to be used clinically to treat melanomas that contain this BRAF mutation. More importantly, since only 60% of melanomas have this mutation, IGFBP7 will not be effective in treating all melanomas. However, by using this protein as a guide we can hopefully identify key drug targets for killing all melanoma cells, and use this knowledge as a platform for therapeutic intervention.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
203258
Name
Billen Lieven P
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Characterization of IGFBP7-mediated apoptosis in oncogenic BRAF melanomas
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Apoptosis; Bcl-2 Proteins; Igf2r; Igfbp7; Map Kinase Pathway; Melanoma; Oncogene Addiction; Stat1
Abstract
Melanoma is a type of cancer that occurs in melanocytes, the pigmented cells of the skin, and is the deadliest form of skin cancer. The incidence of this disease is rising faster than any other cancer (American Cancer Society, 2006) and therapeutic interventions remain only marginally effective. With this in mind, a huge investment is being made to understand melanoma signaling networks in an attempt to identify new targets or combinations of targets for therapeutic intervention.
At the genetic level, greater than 90% of all melanomas show continuous hyperactivity in a particular signaling pathway known as the MAPK pathway, which is responsible for the rapid growth and division of these melanoma cells. In 60% of all melanomas this phenomenon is the result of a particular mutation in the protein BRAF, which is part of the MAPK pathway. Unfortunately drugs that target this pathway do not kill melanoma cells but only slow their growth, which will slow tumour growth but not shrink tumours. Hence these drugs have performed poorly in clinical trials.
The lab of Michael Green at the University of Massachusetts Medical School has discovered that the protein IGFBP7 effective kills melanoma cells that contain this BRAF mutation, shrinking melanoma tumours. The aim of the research proposed here is to fully understand how IGFBP7 kills these cells. This knowledge may further the potential for IGFBP7 to be used clinically to treat melanomas that contain this BRAF mutation. More importantly, since only 60% of melanomas have this mutation, IGFBP7 will not be effective in treating all melanomas. However, by using this protein as a guide we can hopefully identify key drug targets for killing all melanoma cells, and use this knowledge as a platform for therapeutic intervention.
Competitiondate
201002
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Billen, Lieven P
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~